Biohaven (BHVN)

• Market cap: $2.31B
• 1 day: -5.99%
• 5 days: -24.31%
• 1 month: -29.51%
• 3 months: -39.38%
• 6 months: -53.47%
• Year to date: -39.38%
• 1 year: -56.59%
• 5 years: -24.08%
• 10 years: 29.14%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Employees: 256

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

98% more call options, than puts

Call options by funds: $34.9M | Put options by funds: $17.6M

61% more repeat investments, than reductions

Existing positions increased: 103 | Existing positions reduced: 64

18% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 39

0% more funds holding

Funds holding: 253 [Q3] → 254 (+1) [Q4]

0.05% more ownership

Funds ownership: 91.96% [Q3] → 92.01% (+0.05%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 10 [Q3] → 10 (+0) [Q4]

19% less capital invested

Capital invested by funds: $4.34B [Q3] → $3.51B (-$833M) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $54 139% upside
• Avg. target: $62 175% upside
• High target: $68 201% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Morgan Stanley Terence Flynn 37% 1-year accuracy 7 / 19 met price target	179% upside $63	Overweight Maintained	7 Mar 2025
JP Morgan Tessa Romero 31% 1-year accuracy 4 / 13 met price target	201% upside $68	Overweight Maintained	5 Mar 2025
HC Wainwright & Co. Douglas Tsao 23% 1-year accuracy 39 / 171 met price target	139% upside $54	Buy Reiterated	4 Mar 2025
RBC Capital Leonid Timashev 31% 1-year accuracy 13 / 42 met price target	170% upside $61	Outperform Reiterated	4 Mar 2025
Deutsche Bank David Hoang 35% 1-year accuracy 6 / 17 met price target	188% upside $65	Buy Initiated	11 Feb 2025